Chris J. O’Callaghan

13.5k total citations · 4 hit papers
106 papers, 9.1k citations indexed

About

Chris J. O’Callaghan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Chris J. O’Callaghan has authored 106 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Chris J. O’Callaghan's work include Colorectal Cancer Treatments and Studies (39 papers), Genetic factors in colorectal cancer (18 papers) and Gastric Cancer Management and Outcomes (15 papers). Chris J. O’Callaghan is often cited by papers focused on Colorectal Cancer Treatments and Studies (39 papers), Genetic factors in colorectal cancer (18 papers) and Gastric Cancer Management and Outcomes (15 papers). Chris J. O’Callaghan collaborates with scholars based in Canada, Australia and United States. Chris J. O’Callaghan's co-authors include Dongsheng Tu, Derek J. Jonker, Christos S. Karapetis, John Zalcberg, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, R. J. Simes, Christiane Langer and Shirin Khambata‐Ford and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Chris J. O’Callaghan

101 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

2008 2.8k citations Christos S. Karapetis, Derek J. Jonker et al. profile →
Cetuximab for the Treatment of Colorectal Cancer

2007 1.4k citations Derek J. Jonker, Chris J. O’Callaghan et al. profile →
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

2009 708 citations Chris J. O’Callaghan et al. profile →
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 573 citations Derek J. Jonker, Dongsheng Tu et al. profile →

Peers

Chris J. O’Callaghan

ONCOL

PRM

PFM

SURGE

Vittorina Zagonel Italy

Rosalba Miceli Italy

Johannes H.W. de Wilt Netherlands

Irene Floriani Italy

Tamas Hickish United Kingdom

Alberto Zaniboni Italy

Kristine Broglio United States

Enrico Cortesi Italy

Roscoe F. Morton United States

Christophe Tournigand France

Vittorina Zagonel Italy

Chris J. O’Callaghan

5.3k ×0.9

ONCOL

2.4k ×0.8

PRM

3.0k ×1.6

PFM

1.4k ×0.9

SURGE

1.4k ×1.1

Citations per year, relative to Chris J. O’Callaghan Chris J. O’Callaghan (= 1×) peers Vittorina Zagonel

Countries citing papers authored by Chris J. O’Callaghan

Since Specialization

Citations

This map shows the geographic impact of Chris J. O’Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris J. O’Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris J. O’Callaghan more than expected).

Fields of papers citing papers by Chris J. O’Callaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris J. O’Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris J. O’Callaghan. The network helps show where Chris J. O’Callaghan may publish in the future.

Co-authorship network of co-authors of Chris J. O’Callaghan

This figure shows the co-authorship network connecting the top 25 collaborators of Chris J. O’Callaghan. A scholar is included among the top collaborators of Chris J. O’Callaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris J. O’Callaghan. Chris J. O’Callaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Titmuss, Emma, Robert J. Vanner, David F. Schaeffer, et al.. (2024). Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Research Communications. 5(1). 66–73. 2 indexed citations

Titmuss, Emma, Dongsheng Tu, Stephanie Yasmin Brule, et al.. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research. 30(6). 1121–1130. 3 indexed citations

Loree, Jonathan M., Emma Titmuss, James T. Topham, et al.. (2024). Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clinical Cancer Research. 30(15). 3189–3199. 11 indexed citations

Karapetis, Christos S., Michael J. Sorich, Levi Pederson, et al.. (2024). Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer. 130(8). 1269–1278. 2 indexed citations

Jiang, Di, Hao‐Wen Sim, Lillian L. Siu, et al.. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer. 22(4). 457–463.

Deng, Yangqing, Dongsheng Tu, Chris J. O’Callaghan, et al.. (2023). A Bayesian approach for two‐stage multivariate Mendelian randomization with mixed outcomes. Statistics in Medicine. 42(13). 2241–2256. 1 indexed citations

Kopciuk, Karen, Hans J. Vogel, Patricia A. Tang, et al.. (2023). Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer. Cancer Medicine. 12(15). 16019–16031. 5 indexed citations

Deng, Yangqing, Dongsheng Tu, Chris J. O’Callaghan, Geoffrey Liu, & Wei Xu. (2023). Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions. Statistical Methods in Medical Research. 32(8). 1543–1558. 7 indexed citations

Kennecke, Hagen F., Chris J. O’Callaghan, Jonathan M. Loree, et al.. (2022). Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results. Journal of Clinical Oncology. 41(2). 233–242. 31 indexed citations

10.

Song, Andrew, Keyue Ding, Iyad Alnahhas, et al.. (2021). Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial. Neuro-Oncology Advances. 3(1). vdab153–vdab153. 12 indexed citations

11.

Loree, Jonathan M., Dongsheng Tu, Derek J. Jonker, et al.. (2020). Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clinical Cancer Research. 27(1). 52–59. 19 indexed citations

12.

Shepshelovich, Daniel, Amanda Townsend, Osvaldo Espin‐Garcia, et al.. (2018). Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine. 7(11). 5478–5487. 20 indexed citations

13.

Hakim, Alan J., et al.. (2017). Chronic fatigue in Ehlers–Danlos syndrome—Hypermobile type. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 175(1). 175–180. 77 indexed citations

14.

Jonker, Derek J., Louise Nott, Takayuki Yoshino, et al.. (2016). A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27. vi150–vi150. 13 indexed citations

15.

Rahman, Ruman, Teresa Osteso-Ibáñez, Robert A. Hirst, et al.. (2010). Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular Cancer Therapeutics. 9(9). 2568–2581. 31 indexed citations

16.

Perry, James, Chris J. O’Callaghan, Keyue Ding, et al.. (2010). A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. Neuro-Oncology. 12. 38–38. 16 indexed citations

17.

Powell, Erin, Christos S. Karapetis, Derek J. Jonker, et al.. (2010). Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology. 22(1). 118–126. 33 indexed citations

18.

Lewandowski, Krzysztof, Konrad Szosland, Chris J. O’Callaghan, et al.. (2005). Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: A significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Molecular Genetics and Metabolism. 85(1). 61–69. 51 indexed citations

19.

Braitberg, George, et al.. (2001). Impact of a toxicology service on a metropolitan teaching hospital. Emergency Medicine. 13(1). 37–42. 23 indexed citations

20.

O’Callaghan, Chris J., et al.. (1994). Pharmacokinetics of prilocaine in intravenous regional anaesthesia. Emergency Medicine. 6(1). 25–28.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact